{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:47:52Z","timestamp":1791668872087,"version":"4.3.4"},"reference-count":57,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Actinium\u2010225 labeled prostate\u2010specific membrane antigen (PSMA) targeted radionuclide therapy has emerged as a potential treatment option in the management of men with metastatic castrate\u2010resistant prostate cancer (mCRPC). This study investigated molecular imaging\u2010derived parameters and compared imaging response of lesions categorized by tumor site.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Men with mCRPC treated with [225Ac]Ac\u2010J591 from 2017 to 2022 at our center on two prospective trials (NCT03276572 and NCT04506567) with pre\u2010 and post\u2010treatment [68Ga]Ga\u2010PSMA\u201011 Positron Emission Tomography (PET) imaging studies available were included. SUVpeak of the 3 most\u2010 and 3 least\u2010avid lesions of the tumor sites were manually assessed. The median change of the SUVpeak from pre\u2010 to post\u2010treatment per tumor site was evaluated using the paired Wilcox test. An objective response (OR) in the follow\u2010up image was defined as complete or partial response using PET Response Criteria in Solid Tumors (PERCIST) 1.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 46 cases met the criteria for image review; most of them (<jats:italic>n<\/jats:italic>\u2009=\u200925, 54.3%) had more than one tumor site category. In total, 445 PSMA PET\u2010positive lesions were assessed: 220 osseous, 163 nodal, 41 visceral, and 21 prostatic lesions. After treatment with [225Ac]Ac\u2010J591, absolute SUVpeak values per tumor site declined significantly (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) except for prostatic lesions (<jats:italic>p<\/jats:italic>\u2009=\u20091). The PERCIST\u2010OR rate for osseous, nodal, visceral, and prostatic lesions was 53%, 28%, 56%, and 38%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>[225Ac]Ac\u2010J591 is an active treatment in men with mCRPC. Tumor distribution patterns may influence treatment response and potentially prognosis. Our findings warrant further validation in a larger cohort but may be considered in treatment planning and trial design.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.24853","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T06:21:14Z","timestamp":1737699674000},"page":"502-509","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Baseline Imaging Derived Factors of Response Following [225Ac]Ac\u2010J591 Therapy in Metastatic Castration\u2010Resistant Prostate Cancer: A Lesion Level Analysis"],"prefix":"10.1002","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-2445","authenticated-orcid":false,"given":"Judith","family":"Stangl\u2010Kremser","sequence":"first","affiliation":[{"name":"Department of Urology Weill Cornell Medicine New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Ricaurte\u2010Fajardo","sequence":"additional","affiliation":[{"name":"Division of Molecular Imaging and Therapeutics, Department of Radiology Weill Cornell Medicine New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Huicochea Castellanos","sequence":"additional","affiliation":[{"name":"Division of Molecular Imaging and Therapeutics, Department of Radiology Weill Cornell Medicine New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Martinez\u2010Fundichely","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics Weill Cornell Medicine New York City New York USA"},{"name":"Institute for Computational Biomedicine, Weill Cornell Medicine New York City New York USA"},{"name":"Meyer Cancer Center, Weill Cornell Medicine New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Weill Cornell Medicine New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Osborne","sequence":"additional","affiliation":[{"name":"Division of Molecular Imaging and Therapeutics, Department of Radiology Weill Cornell Medicine New York City New York USA"},{"name":"Meyer Cancer Center, Weill Cornell Medicine New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jones T.","family":"Nauseef","sequence":"additional","affiliation":[{"name":"Meyer Cancer Center, Weill Cornell Medicine New York City New York USA"},{"name":"Division of Hematology and Medical Oncology Weill Cornell Medicine New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[{"name":"Department of Urology Weill Cornell Medicine New York City New York USA"},{"name":"Meyer Cancer Center, Weill Cornell Medicine New York City New York USA"},{"name":"Division of Hematology and Medical Oncology Weill Cornell Medicine New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Bander","sequence":"additional","affiliation":[{"name":"Department of Urology Weill Cornell Medicine New York City New York USA"},{"name":"Meyer Cancer Center, Weill Cornell Medicine New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"7","key":"e_1_2_12_2_1","first-page":"1807","article-title":"Expression of the Prostate\u2010Specific Membrane Antigen","volume":"54","author":"Israeli R. S.","year":"1994","journal-title":"Cancer Research"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/1078-1439(95)00002-y"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123216"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0226"},{"issue":"5","key":"e_1_2_12_6_1","first-page":"927","article-title":"Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients","volume":"7","author":"Horoszewicz J. S.","year":"1987","journal-title":"Anticancer Research"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/1078-1439(95)00004-2"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0045(19970301)30:4<232::aid-pros2>3.0.co;2-n"},{"issue":"17","key":"e_1_2_12_9_1","first-page":"3629","article-title":"Monoclonal Antibodies to the Extracellular Domain of Prostate\u2010Specific Membrane Antigen Also React With Tumor Vascular Endothelium","volume":"57","author":"Liu H.","year":"1997","journal-title":"Cancer Research"},{"issue":"18","key":"e_1_2_12_10_1","first-page":"4055","article-title":"Constitutive and Antibody\u2010Induced Internalization of Prostate\u2010Specific Membrane Antigen","volume":"58","author":"Liu H.","year":"1998","journal-title":"Cancer Research"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63239-7"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.284"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031158"},{"key":"e_1_2_12_14_1","unstructured":"C. for D. E. and Research \u201cFDA D.I.S.C.O.: Burst Edition: FDA Approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the Treatment of Adult Patients With Prostate\u2010Specific Membrane Antigen\u2010Positive Metastatic Castration\u2010Resistant Prostate Cancer Who Have Been Treated With Androgen Receptor Pathway Inhibition and Taxane\u2010Based Chemotherapy \u201d FDA Jul. 2022 Accessed: May 10 2023 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-pluvicto-lutetium-lu-177-vipivotide-tetraxetan-treatment-adult."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"e_1_2_12_16_1","unstructured":"\u201cESMO 2024: Efficacy of 177Lu\u2010PNT2002 in PSMA\u2010Positive mCRPC Following Progression on an Androgen\u2010Receptor Pathway Inhibitor (SPLASH).\u201d Accessed: Dec. 10 2024 https:\/\/www.urotoday.com\/conference-highlights\/esmo-2024\/esmo-2024-prostate-cancer\/154850-esmo-2024-efficacy-of-177lu-pnt2002-in-psma-positive-mcrpc-following-progression-on-an-androgen-receptor-pathway-inhibitor-splash.html."},{"key":"e_1_2_12_17_1","unstructured":"\u201cECLIPSE Trial: 177Lu\u2010PSMA\u2010I&T Extends rPFS vs\u00a0Hormone Therapy in mCRPC \u201d Urology Times. Accessed: Dec. 10 2024 https:\/\/www.urologytimes.com\/view\/eclipse-trial-177lu-psma-i-t-extends-rpfs-vs-hormone-therapy-in-mcrpc."},{"key":"e_1_2_12_18_1","unstructured":"Endocyte \u201cAcTION: A Phase I Study of [225Ac]Ac\u2010PSMA\u2010617 in Men With PSMA\u2010Positive Prostate Cancer With or Without Prior [177Lu]Lu\u2010PSMA\u2010617 Radioligand Therapy \u201d clinicaltrials.gov Clinical trial registration NCT04597411 Nov. 2024. Accessed: Dec. 10 2024 https:\/\/clinicaltrials.gov\/study\/NCT04597411."},{"key":"e_1_2_12_19_1","unstructured":"T.BrabanderandI.PhaseDose Escalation Study to Evaluate Tolerability and Safety of 225Ac\u2010PSMA I&T in Patients With Metastatic Prostate Cancer \u201d clinicaltrials.gov Clinical trial registration NCT05902247 Jun. 2023. Accessed: Dec. 10 2024 https:\/\/clinicaltrials.gov\/study\/NCT05902247."},{"key":"e_1_2_12_20_1","unstructured":"Weill Medical College of Cornell University \u201cPhase I\/II Trial of Pembrolizumab and Androgen\u2010Receptor Pathway Inhibitor With or Without 225Ac\u2010J591 for Progressive Metastatic Castration Resistant Prostate Cancer \u201d clinicaltrials.gov Clinical trial registration NCT04946370 Oct. 2024. Accessed: Dec. 10 2024 https:\/\/clinicaltrials.gov\/study\/NCT04946370."},{"key":"e_1_2_12_21_1","unstructured":"Bayer \u201cA Phase 1 Open\u2010label First\u2010in\u2010human Multicenter Study to Evaluate the Safety Tolerability Pharmacokinetics and Antitumor Activity of Actinium\u2010225\u2010Macropa\u2010Pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC) \u201d clinicaltrials.gov Clinical trial registration NCT06052306 Nov. 2024. Accessed: Dec. 10 2024 https:\/\/clinicaltrials.gov\/study\/NCT06052306."},{"key":"e_1_2_12_22_1","unstructured":"\u201cFull Text.\u201d Accessed: Apr. 09 2024 https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/26\/2\/ERC-18-0226.pdf."},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00638-1"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30080529"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231179309"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.12.002"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23919"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00573"},{"key":"e_1_2_12_29_1","unstructured":"Weill Medical College of Cornell University \u201cPhase I\/II Dose\u2010escalation Study of Fractionated and Multiple Dose 225Ac\u2010J591 for Progressive Metastatic Castration Resistant Prostate Cancer \u201d clinicaltrials.gov Clinical trial registration NCT04506567 Jul. 2024. Accessed: Dec. 11 2024 https:\/\/clinicaltrials.gov\/study\/NCT04506567."},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS288"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3670-z"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050699"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544100-00004"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-004-1566-1"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.054239"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-006-0224-1"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a033688"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114530"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-021-00716-0"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2012.4"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-007-9116-4"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26789"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20210097"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003307"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2021.06.007"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2020200058"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.14670\/HH-29.1263"},{"issue":"4","key":"e_1_2_12_53_1","first-page":"273","article-title":"Neuroendocrine Differentiation of Prostate Cancer: A Review","volume":"2","author":"Parimi V.","year":"2014","journal-title":"American Journal of Clinical and Experimental Urology"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.03.010"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04328-1"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071575"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-0895-5078"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.01.002"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T08:20:31Z","timestamp":1740558031000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.24853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/pros.24853"],"URL":"https:\/\/doi.org\/10.1002\/pros.24853","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"2024-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}